Vistin Pharma ASA: Invitation to Q4 2024 conference call
06 Fevereiro 2025 - 7:00AM
UK Regulatory
Vistin Pharma ASA: Invitation to Q4 2024 conference call
Oslo, Norway, 6 February 2025
Vistin Pharma ASA will release its fourth quarter and
preliminary 2024 results on Thursday 13th of February 2025. Vistin
Pharma will host a conference call for all shareholders and
interested parties at the same day at 08:30 CET. There will be a
Q&A session following the management discussion.
The conference call will be held in English.
The fourth quarter conference call will be available via web and
audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/ekueptdm
Telephone conference (online registration):
https://register.vevent.com/register/BI6693743078794f05ac2e84522925591f
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com
About Vistin Pharma | www.vistin.com
Vistin Pharma is a Norwegian pharmaceutical company
producing Metformin Hydrochloride (API). The Metformin is also
available as Direct Compressible lubricated granules. As a solely
dedicated European Metformin producer, Vistin Pharma is a
well-positioned supplier to leading pharmaceutical companies.
Vistin Pharma is headquartered in Oslo, Norway, and has highly
qualified employees and a dedicated manufacturing facility in
Kragerø.
This information is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act
Vistin Pharma Asa (LSE:0RAM)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Vistin Pharma Asa (LSE:0RAM)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025